Denali Therapeutics (NASDAQ:DNLI) Stock Rating Upgraded by Wall Street Zen

Key Points

• Wall Street Zen raised Denali Therapeutics from a “strong sell” to a “sell,” while the broader analyst community remains more positive overall with a consensus rating of Moderate Buy.
• The company reported a quarterly EPS loss of ($0.69), beating analyst expectations of ($0.73), though Denali is still expected to post a full-year loss.
• Denali shares were down about 0.5% and traded at $19.62; the stock remains backed heavily by institutions, which own about 92.92% of the company.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) was upgraded by Wall Street Zen from a "strong sell" rating to a "sell" rating in a research note issued to investors on Saturday.

Other equities analysts have also issued research reports about the stock. Wedbush dropped their target price on shares of Denali Therapeutics from $25.00 to $23.00 and set an "outperform" rating on the stock in a research report on Friday. BTIG Research boosted their target price on shares of Denali Therapeutics from $36.00 to $38.00 and gave the stock a "buy" rating in a research report on Wednesday, March 25th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Denali Therapeutics in a research report on Monday, April 20th. Robert W. Baird lifted their price target on shares of Denali Therapeutics from $32.00 to $34.00 and gave the stock an "outperform" rating in a research note on Tuesday, April 7th. Finally, Stifel Nicolaus lifted their price target on shares of Denali Therapeutics from $34.00 to $41.00 and gave the stock a "buy" rating in a research note on Thursday, March 26th. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $34.42.

Denali Therapeutics Trading Down 0.5%

Shares of DNLI stock opened at $19.62 on Friday. Denali Therapeutics has a 1 year low of $12.58 and a 1 year high of $23.77. The firm's fifty day simple moving average is $20.19 and its 200 day simple moving average is $18.86. The firm has a market capitalization of $3.11 billion, a P/E ratio of -6.81 and a beta of 0.99. The company has a current ratio of 9.16, a quick ratio of 9.16 and a debt-to-equity ratio of 0.01.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last announced its earnings results on Tuesday, May 5th. The company reported ($0.69) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.73) by $0.04. During the same quarter in the prior year, the business posted ($0.78) EPS. As a group, sell-side analysts predict that Denali Therapeutics will post -2.86 EPS for the current year.

Institutional Investors Weigh In On Denali Therapeutics

Institutional investors have recently bought and sold shares of the business. Foresite Capital Management VI LLC acquired a new stake in shares of Denali Therapeutics in the 3rd quarter valued at $14,520,000. AlphaQuest LLC boosted its stake in shares of Denali Therapeutics by 224.1% in the 3rd quarter. AlphaQuest LLC now owns 74,422 shares of the company's stock valued at $1,081,000 after purchasing an additional 51,458 shares in the last quarter. Aberdeen Group plc boosted its stake in shares of Denali Therapeutics by 23.4% in the 3rd quarter. Aberdeen Group plc now owns 1,113,586 shares of the company's stock valued at $16,169,000 after purchasing an additional 210,835 shares in the last quarter. Principal Financial Group Inc. boosted its stake in shares of Denali Therapeutics by 18.5% in the 3rd quarter. Principal Financial Group Inc. now owns 1,271,190 shares of the company's stock valued at $18,458,000 after purchasing an additional 198,207 shares in the last quarter. Finally, Capricorn Fund Managers Ltd acquired a new stake in shares of Denali Therapeutics in the 4th quarter valued at $1,027,000. Institutional investors and hedge funds own 92.92% of the company's stock.

About Denali Therapeutics

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company's research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali's approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali's lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson's disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer's patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.